Vaderis' $152M to fund ph. 3 trial in rare blood vessel disorder
Vaderis' $152M to fund ph. 3 trial in rare blood vessel disorder
Vaderis Therapeutics
Private
Clinical-stage biotech developing treatments for rare orphan diseases caused by vascular malformations. Lead program for HHT (Hereditary Hemorrhagic Telangiectasia). FDA Fast Track designation.
Company Info
Sector:Rare Disease / Vascular
Headquarters:Basel, Switzerland
Founded:2019
Website:vaderis.com/
Funding Round:Series B ($152M)
Total Funding:~$170M
Funding & Investor Relations
Notable Investors
- Jeito Capital
- Forbion
- Novo Holdings
Upcoming Milestones & Key Dates
2027
Clinical Data
Phase 3 HHT data expected
2026 H2
Clinical Data
Phase 2 vascular malformations interim update
Clinical Development Pipeline
VAD044
Target: Anti-angiogenicVAD044
Target: Anti-angiogenicRecent News
Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3
Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3
Leadership Team
Paolo Ferrario
Chief Executive Officer
Arnaud Bayle
Chief Scientific Officer
Carlo Incerti
Chairman of the Board